Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer
- PMID: 35021198
- DOI: 10.1093/ajhp/zxac008
Misconception on the duration of ado-trastuzumab emtansine treatment for HER2-positive early breast cancer
Keywords: HER2; ad-trastuzumab emtansine; adjuvant; early breast cancer.
Comment on
-
Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.J Clin Oncol. 2021 Feb 20;39(6):685-693. doi: 10.1200/JCO.20.02510. Epub 2020 Oct 20. J Clin Oncol. 2021. PMID: 33079579
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
